An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
2 Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
3 Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
4 Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
5 Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
6 Department of Dermatology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
7 Department of Dermatology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
8 First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
9 Department of Dermatology-Venereology, Faculty of Medicine, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
10 Department of Dermatology and Venereology, Medical Faculty of the Military Medical Academy, University of Defense, Belgrade, Serbia.
11 Department of Dermatology, Venerology and Oncodermatology, University of Pécs, Pécs, Hungary.
12 Dermatology Unit, Department of Surgical and Medical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
13 Division of Medical Oncology, Fondazione Policlinico "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Rome, Italy.
14 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
15 Department of Dermatology, University Hospital of Heraklion, Heraklion, Greece.
16 Dermatology Department, Hospital Germans Trias I Pujol de Badalona, Badalona, Spain.
17 Carol Davila University of Medicine and Pharmacy Bucharest, Department of Oncologic Dermatology, Elias University Hospital Bucharest, Bucharest, Romania.
18 Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
19 Department of Dermatology, Hospital Ruber de Juan Bravo, Universidad Europea, Madrid, Spain.
20 Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
21 Department of Dermatology, Rambam Health Care Campus.
22 The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
23 Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
24 CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute, Lille, France.
25 Oncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
1 Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
2 Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
3 Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
4 Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
5 Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
6 Department of Dermatology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
7 Department of Dermatology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
8 First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
9 Department of Dermatology-Venereology, Faculty of Medicine, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
10 Department of Dermatology and Venereology, Medical Faculty of the Military Medical Academy, University of Defense, Belgrade, Serbia.
11 Department of Dermatology, Venerology and Oncodermatology, University of Pécs, Pécs, Hungary.
12 Dermatology Unit, Department of Surgical and Medical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
13 Division of Medical Oncology, Fondazione Policlinico "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Rome, Italy.
14 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
15 Department of Dermatology, University Hospital of Heraklion, Heraklion, Greece.
16 Dermatology Department, Hospital Germans Trias I Pujol de Badalona, Badalona, Spain.
17 Carol Davila University of Medicine and Pharmacy Bucharest, Department of Oncologic Dermatology, Elias University Hospital Bucharest, Bucharest, Romania.
18 Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
19 Department of Dermatology, Hospital Ruber de Juan Bravo, Universidad Europea, Madrid, Spain.
20 Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
21 Department of Dermatology, Rambam Health Care Campus.
22 The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
23 Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
24 CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute, Lille, France.
25 Oncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
This retrospective case series compares vitiligo resulting from immune checkpoint inhibitor (ICI) therapy vs preexisting vitiligo among patients receiving ICI treatment for cancer.
Conflict of Interest Disclosures: Dr Kraehenbuehl reported personal fees from Janssen (intermittent consultant) outside the submitted work. Dr Elshot reported personal fees from Bristol Myers Squibb and MSD outside the submitted work. Dr Peris reported personal fees from advisory board meetings of AbbVie, Almirall, Beiersdorf, Bristol Myers Squibb, Galderma, Lilly, Sanofi, and Sunpharma and consulting fees from Philogen outside the submitted work. Dr Rossi reported personal fees from MSD, Immunocore, Bristol Myers Squibb, Novartis, Pierre Fabre, Pfizer, and Gentili outside the submitted work. Dr Freites-Martinez reported personal fees from Galderma Spain, ISDIN Spain, SHB, and Cantabria Labs Spain and nonfinancial support from Lilly Spain outside the submitted work. Dr Peuvrel reported nonfinancial support from Bristol Myers Squibb, Pierre Fabre Oncology, and Novartis and personal fees from Novartis and Pierre Fabre Oncology outside the submitted work. Dr Sibaud reported personal fees from Bristol Myers Squibb and MSD during the conduct of the study and personal fees from AstraZeneca, Pierre Fabre, Novartis, Bayer, Astellas Pharma, Janssen, Incyte, and L’Oreal outside the submitted work. No other disclosures were reported.
References
Tang K, Seo J, Tiu BC, et al. . Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy. JAMA Dermatol. 2022;158(2):189-193. doi:10.1001/jamadermatol.2021.5476
-
DOI
-
PMC
-
PubMed
Wongvibulsin S, Pahalyants V, Kalinich M, et al. . Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563-572. doi:10.1016/j.jaad.2021.03.094
-
DOI
-
PMC
-
PubMed
Le TK, Brown I, Goldberg R, et al. . Cutaneous toxicities associated with immune checkpoint inhibitors: an observational, pharmacovigilance study. J Invest Dermatol. 2022;142(11):2896-2908.e4. doi:10.1016/j.jid.2022.04.020
-
DOI
-
PMC
-
PubMed
Hua C, Boussemart L, Mateus C, et al. . Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45-51. doi:10.1001/jamadermatol.2015.2707
-
DOI
-
PubMed
Zhang S, Tang K, Wan G, et al. . Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study. J Am Acad Dermatol. 2023;88(5):1024-1032. doi:10.1016/j.jaad.2022.12.048
-
DOI
-
PMC
-
PubMed
